Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone graft

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    231 result(s) found for: Bone graft. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-004420-37 Sponsor Protocol Number: 280 Start Date*: 2007-05-29
    Sponsor Name:OSIRIS
    Full Title: ﾓA Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymalﾙ (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment o...
    Medical condition: Subjects must have steroid refractory treatment of Grades B-D acute GVHD secondary to allogeneic HSCT (stem cells sources: bone marrow, peripheral blood stem cells, or cord blood cells) or DLI.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018651 Graft versus host disease LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005019-81 Sponsor Protocol Number: INO-0106 Start Date*: 2006-12-22
    Sponsor Name:OPi
    Full Title: A European Open-Label, Multicentre, Phase II Study of Inolimomab in the Treatment of Primary Steroid Resistant Acute Graft versus Host Disease (aGvHD) following allogeneic Stem Cell Transplantation...
    Medical condition: For treatment of patients with Primary Steroid Resistant Acute Graft versus Host Disease (aGvHD) following allogeneic Stem Cell Transplantation for Hematological Malignancies in Adult patients
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018651 Graft versus host disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004310-14 Sponsor Protocol Number: TJB0703 Start Date*: 2007-12-13
    Sponsor Name:CHU-ULG
    Full Title: Infusion of mesenchymal stem cells as treatment for steroid resistant grade II to IV acute GVHD or poor graft function: a multicenter phase II study
    Medical condition: Steroid resistant grade II to IV acute graft-versus-host disease (GVHD) or poor graft function after allogeneic hematopoietic cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10001756 Allogenic bone marrow transplantation therapy PT
    21.1 10042613 - Surgical and medical procedures 10045553 Unrelated donor bone marrow transplantation therapy PT
    20.0 10021428 - Immune system disorders 10018799 GVHD LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004529-57 Sponsor Protocol Number: EQ-100-02 Start Date*: 2022-06-24
    Sponsor Name:Equillium Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease
    Medical condition: Acute Graft Versus Host Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10018799 GVHD LLT
    22.0 100000004865 10059044 Allogeneic peripheral hematopoietic stem cell transplant LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-001925-27 Sponsor Protocol Number: 06-MI-04 Start Date*: 2009-10-05
    Sponsor Name:Great Ormond Street Hospital For Children NHS Trust
    Full Title: Phase I/II clinical trial of T cell suicide gene therapy following haploidentical stem cell transplantation
    Medical condition: Graft-versus-host disease (GVHD) resulting from haploidentical bone marrow or blood stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018651 Graft versus host disease LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024297-19 Sponsor Protocol Number: TJB1016P1 Start Date*: 2011-09-13
    Sponsor Name:CHU de Liege
    Full Title: Allogeneic hematopoietic cell transplantation from HLA-matched donors after reduced-intensity conditioning: a phase II randomized study comparing 2 GVHD prophylaxis regimen
    Medical condition: Hematologic malignancies treated by reduced-intensity conditioning allogeneic transplants.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10042613 - Surgical and medical procedures 10001756 Allogenic bone marrow transplantation therapy PT
    18.0 100000004870 10018799 GVHD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-006178-86 Sponsor Protocol Number: EBMT-LE-0601 Start Date*: 2007-08-03
    Sponsor Name:European group for Blood and Marrow Transplantation
    Full Title: A randomized placebo-controlled trial comparing cyclosporine plus steroids with or without Myfortic® as primary treatment for extensive chronic graft-versus host disease
    Medical condition: patients with newly diagnosed (first episode) extensive chronic Graft versus Host Disease (cGvHD) post allogeneic transplantation for any primary diagnosis
    Disease: Version SOC Term Classification Code Term Level
    7 10018651 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) ES (Ongoing) SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022780-35 Sponsor Protocol Number: 10-005 Start Date*: 2011-07-06
    Sponsor Name:THERAKOS, Inc.
    Full Title: A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy with UVADEX™ for the Treatment of Patients with Moderate to Severe Chronic Graft-versus-Host Disease (cGvHD)
    Medical condition: Chronic graft-versus-host disease (cGvHD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10018651 Graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) AT (Completed) ES (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2019-000894-22 Sponsor Protocol Number: MAGIC-HR-ECP Start Date*: 2019-12-10
    Sponsor Name:Department of Stem Cell Transplantation - University Medical Center Hamburg-Eppendorf
    Full Title: Phase II multicenter study of extracorporeal photopheresis with UvadexTM plus standard steroid treatment for high risk acute Graft-versus-Host Disease
    Medical condition: New onset high risk acute GvHD following allogeneic SCT
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10018653 Graft-versus-host disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002503-26 Sponsor Protocol Number: X16082 Start Date*: 2017-03-14
    Sponsor Name:Fundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI)
    Full Title: Phase Ib/II trial to evaluate safety and efficacy of oral ixazomib in combination with sirolimus and tacrolimus in the prophylaxis of chronic graft-versus-host disease
    Medical condition: Adult patiens after allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004870 10018653 Graft-versus-host disease LLT
    19.1 100000004865 10067859 Allogenic stem cell transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002310-22 Sponsor Protocol Number: 35/2008/O/Sper Start Date*: 2008-06-16
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: A multicenter phase II trial of Recipient pre-treatment with Short-Term Rapamycin for the prevention of acute GVHD after hematopoietic stem cell transplantation in Elderly Patients
    Medical condition: Graft Versus Host Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048396 Bone marrow transplant rejection LLT
    9.1 10000802 Acute GVH disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018594-37 Sponsor Protocol Number: EMN-alloRIC2010 Start Date*: 2013-01-24
    Sponsor Name:European Myeloma Network
    Full Title: European Myeloma Network sequential phase I / phase II trial on RIC allogeneic transplantation: an optimized program for high risk relapsed patients
    Medical condition: Allogeneic transplantation for patients with multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10059041 Allogeneic peripheral haematopoietic stem cell transplant LLT
    14.1 10021428 - Immune system disorders 10018651 Graft versus host disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004806-14 Sponsor Protocol Number: TKS-2014-001 Start Date*: Information not available in EudraCT
    Sponsor Name:Therakos, Inc.
    Full Title: Single-Arm Study to Assess the Efficacy of UVADEX® (methoxsalen) Sterile Solution in Conjunction with the THERAKOS® CELLEX® Photopheresis System in Pediatric Patients with Steroid-Refractory Acute ...
    Medical condition: Acute graft-versus-host disease (aGvHD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10018651 Graft versus host disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GB (Completed) IT (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006577-25 Sponsor Protocol Number: 070101 Start Date*: 2007-07-25
    Sponsor Name:Karolinska Institutet
    Full Title: A prospective randomized study comparing rapamune and tacrolimus vs. cyclosporine and methotrexate as immune prophylaxis in allogeneic hematopoietic stem cell transplantation, using HLA-A, -B, -DRB...
    Medical condition: Graft versus host disease prophylaxis in patients receiving stem cell transplantation due to: chronic myeloid leukemia (CML) in 1st or 2nd chronic phase, acute myeloid leukemia (AML) in complete re...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018799 GVHD LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2008-005862-30 Sponsor Protocol Number: MHH-Pre-GvHD-001 Start Date*: 2009-02-23
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: Pre-emptive therapy of acute graft versus host disease according to specific proteomic patterns after allogeneic hematopoietic stem cell transplantation.
    Medical condition: Pre-emptive therapy of acute graft versus host disease with prednisolone according to specific proteomic patterns after allogeneic hematopoietic stem cell transplantation.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004870 10018652 Graft versus host reaction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000862-31 Sponsor Protocol Number: GLAS Start Date*: 2017-09-28
    Sponsor Name:Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH)
    Full Title: A phase Ib/IIa pilot trial of the oral Hedgehog Signalling Inhibitor, Glasdegib, in Patients with sclerotic chronic graft-versus-host disease refractory to second-line treatment
    Medical condition: Adult patiens with sclerotic chronic graft-versus-host disease refractory to second-line treatment.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000109195 10074474 Transplantation complications HLT
    20.0 100000022080 10067862 Allogeneic stem cell transplantation LLT
    20.0 10022117 - Injury, poisoning and procedural complications 10074555 Transplantation complication PT
    20.0 100000020501 10018653 Graft-versus-host disease LLT
    20.0 100000022080 10067859 Allogenic stem cell transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000538-78 Sponsor Protocol Number: INCB39110-301 Start Date*: 2017-09-14
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft Versus-Host Disease
    Medical condition: Male or female, 18 years of age or older who have received an allogeneic hematopoietic stem cell transplant (allo-HSCT) and have developed Grade II to IV acute GVHD
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    20.1 10021428 - Immune system disorders 10066262 Acute graft versus host disease in skin PT
    20.1 10021428 - Immune system disorders 10066264 Acute graft versus host disease in intestine PT
    20.1 10021428 - Immune system disorders 10066263 Acute graft versus host disease in liver PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) BE (Completed) AT (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) GR (Completed) FI (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005009-24 Sponsor Protocol Number: INO-0107 Start Date*: 2008-05-15
    Sponsor Name:EUSA Pharma
    Full Title: An international randomised, multicentre, parallel-group, Phase III comparative study of inolimomab against usual care in the Treatment of Primary Steroid Refractory Acute Graft versus Host Disease...
    Medical condition: Steroid refractory acute Graft versus Host Disease (aGvHD) after Allogeneic Haematopoietic Stem Cell Transplantation in adult patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018651 Graft versus host disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003237-33 Sponsor Protocol Number: HO112 Start Date*: 2013-11-21
    Sponsor Name:HOVON Foundation
    Full Title: Treatment of severe GVHD after allogeneic hematopoietic stem cell transplanatation with MSCs and steroid versus steroids alone. A prospective double-blind placebo-controlled randomized phase III t...
    Medical condition: Graft Versus Host Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    18.0 10021428 - Immune system disorders 10068908 AGVHD LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000232-91 Sponsor Protocol Number: AP-AS-21-DE Start Date*: 2004-11-15
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: GvHD prophylaxis with ATG-Fresenius S in allogeneic Stem Cell Transplantation from matched unrelated donors: A randomised phase III multicenter trial comparing a standard GvHD prophylaxis with cycl...
    Medical condition: AML, ALL, MDS, CML
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 20:05:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA